BioCentury | Feb 9, 2018
Clinical News
Immunovaccine reports Phase Ib data of DPX-Survivac plus epacadostat for ovarian cancer
...ovarian cancer in the first dose cohort of a Phase Ib trial showing that subcutaneous DPX-Survivac...
...Preliminary data from the first three evaluable patients in the second dose cohort showed that DPX-Survivac...
...TILs). Secondary endpoints include ORR, duration of response, time to progression and overall survival (OS). DPX-Survivac...
...Preliminary data from the first three evaluable patients in the second dose cohort showed that DPX-Survivac...
...TILs). Secondary endpoints include ORR, duration of response, time to progression and overall survival (OS). DPX-Survivac...